A
AKASA (Alpha Health)
Autonomously navigate the complex state of medical reimbursement in the United States
About AKASA (Alpha Health)
AKASA is a technology startup that operates in the healthcare sector, providing innovative solutions to improve efficiency and revenue outcomes. The company's primary offering is a unique blend of computer vision-based Robotic Process Automation (RPA), machine learning, and human-in-the-loop automation. This technology is designed to streamline complex Revenue Cycle Management (RCM) workflows, allowing healthcare staff to focus on more meaningful tasks.
The company's services are primarily targeted at healthcare organizations that are grappling with operational inefficiencies, particularly in their revenue cycle departments. These organizations often operate on thin margins and are in dire need of solutions that can enhance accuracy, transparency, and scalability in their operations.
AKASA's business model is centered on providing these organizations with advanced automation technologies that can solve their most significant RCM problems. By improving operational efficiency, AKASA helps these organizations drive revenue, create efficiencies, and enhance the patient experience.
One of the key ways AKASA generates revenue is by helping healthcare organizations increase their gross yield. For instance, Methodist Health System, one of AKASA's clients, saw a $30M gross yield increase after working with the company.
In summary, AKASA is a healthcare technology startup that leverages advanced automation technologies to improve operational efficiency and revenue outcomes for healthcare organizations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 223
- Open positions
- 6
- Dealroom signal
- 81.6/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Core AI, Robotic Process Automation, Tech for Hospitals and Clinics, Hard Tech, AI Applications
- Technology
- Artificial Intelligence
- Business model
- SaaS
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2024 | $120M | $480M | Undisclosed | — |
| SERIES BOther financing | Mar 2021 | $60M | $240M | Bond · Andreessen Horowitz · Costanoa Ventures | — |
Growth signals
Latest recorded traffic for AKASA (Alpha Health) is 19K monthly website visits, up 11.8% over the last three months. AKASA (Alpha Health)'s team grew 5.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AKASA (Alpha Health) in the South San Francisco ecosystem
The AKASA (Alpha Health) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Andreessen Horowitz
Refactor Capital
Costanoa Ventures
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AKASA (Alpha Health) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AKASA (Alpha Health)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










